LOS ANGELES, December 2, 2011 /PRNewswire/ -- WestPark Capital, Inc. announced the completion of a public offering for IsoRay, Inc. (NYSE Amex: ISR). A total of 2,817,988 shares of common stock and warrants to purchase up to 563,598 shares of common stock were sold, generating gross proceeds of $2,592,549 in the offering. Proceeds from the offering will be used to fund new applications for IsoRay's Cesium-131 technology to treat lung, head and neck, breast and brain cancers, and for working capital and general corporate purposes. WestPark Capital, Inc. acted as lead manager for the offering. This offering was originated through Tekesta Capital Partners, a division of WestPark Capital, Inc.
This press release does not constitute an offer to sell or the solicitation of offers to buy any security and shall not constitute an offer, solicitation, or sale of any security in any jurisdiction in which such offer, solicitation, or sale would be unlawful. The offering was made only by prospectus. A prospectus supplement relating to the common stock and warrants issued in the offering has been declared effective by the Securities and Exchange Commission. Copies of the prospectus supplement and accompanying base prospectus may be obtained at the SEC website at www.sec.gov, or via written request to WestPark Capital, Inc., 1900 Avenue of the Stars, Suite 310, Los Angeles, California 90067.
About WestPark Capital, Inc.WestPark Capital is a leading investment banking and securities brokerage firm serving the needs of private and public growth companies worldwide. WestPark is committed to forging lasting partnerships with emerging growth companies and the investors who back them. WestPark provides a comprehensive range of corporate finance services, including initial public offerings, reverse mergers, follow-on offerings, private placements and corporate finance advisory services. Additional information about WestPark Capital, Inc. is available at www.wpcapital.com or at email@example.com. About IsoRay, Inc.